Oramed Pharmaceuticals (ORMP) said on Monday it has closed on a $36.9 million strategic investment in Alpha Tau Medical (DRTS), acquiring 14.1 million of the clinical-stage oncology therapeutics company's shares at $2.61 apiece.
Under terms of their collaboration agreement, Oramed will provide investor and shareholder outreach support to Alpha Tau over the next three years along with other business and capital markets expertise. It also will take on an active role in governance at Alpha Tau and will select two new members to the company's board of directors.
After first paying costs associated with the now-completed stock sale, Alpha Tau is planning to use the net proceeds for general corporate purposes, including research and development as well as expanding its production capacities and commercialization of its product candidates.
Alpha Tau shares recently were down over 1% while Oramed was falling about 1.3% during Monday trading.
Price: 2.30, Change: -0.03, Percent Change: -1.29
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。